Expanded Access to Ladiratuzumab Vedotin for Patients with Advanced Solid Tumors

Sponsor: Seagen Inc.

Expanded Access

Sponsor score: 60

Inactive

ClinicalTrials ID:NCT06362590

This program offers eligible patients with advanced solid tumors the opportunity to receive treatment with Ladiratuzumab Vedotin, as part of the SGNLVA-005 study.

Patient Parameters

Parameter	Options

Program Overview

The goal of this program is to provide access to the drug Ladiratuzumab Vedotin for patients with advanced solid tumors who qualify for the SGNLVA-005 study. This allows patients who meet certain criteria to receive this treatment option.

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.